Atul Dandekar - 29 Jan 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
CSBO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
29 Jan 2026
Net transactions value
-$253,840
Form type
4
Filing time
02 Feb 2026, 16:21:38 UTC
Previous filing
31 Dec 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dandekar Atul CSBO C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO /s/ Courtney Phillips, as attorney-in-fact 02 Feb 2026 0002050167

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MAZE Common Stock Options Exercise $78,150 +7,500 +71% $10.42 18,003 29 Jan 2026 Direct F1
transaction MAZE Common Stock Sale $51,821 -1,200 -6.7% $43.18 16,803 29 Jan 2026 Direct F1, F2
transaction MAZE Common Stock Sale $154,147 -3,500 -21% $44.04 13,303 29 Jan 2026 Direct F1, F3
transaction MAZE Common Stock Sale $126,022 -2,800 -21% $45.01 10,503 29 Jan 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MAZE Stock Option (Right to Buy) Options Exercise $0 -7,500 -10% $0.000000 66,643 29 Jan 2026 Common Stock 7,500 $10.42 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.49 per share, inclusive.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.53 per share, inclusive.
F5 The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.